CONNECT BIOPHARMA HOLDINGS L (CNTB) Forecast, Price Target & Analyst Ratings

Name: CONNECT BIOPHARMA HOLDINGS L (CNTB) Analyst Consensus Rating
Brand: CONNECT BIOPHARMA HOLDINGS L
Rating: 8.5 (11 reviews)

NASDAQ:CNTB • KYG235491019

3.455 USD

-0.23 (-6.37%)

Last: Mar 27, 2026, 02:38 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CONNECT BIOPHARMA HOLDINGS L (CNTB).

Consensus Price Target

Price Target

$8.06

+ 133.23% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: N/A
Period: Q4 / 2025
EPS Estimate: -$1.44
Revenue Estimate: 3.825K

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

85.45%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$8.06

Upside

+ 133.23%

From current price of $3.46 to mean target of $8.06, Based on 11 analyst forecasts

Low

$6.06

Median

$7.65

High

$10.50

Price Target Revisions

1 Month

0.00%

3 Months

0.00%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for CNTB. The average price target is 8.06 USD. This implies a price increase of 133.23% is expected in the next year compared to the current price of 3.455.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

85.45%

CNTB was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CNTB.

In the previous month the buy percentage consensus was at a similar level.

CNTB was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2025-12-01	Lake Street	Initiate	Buy
2025-11-13	BTIG	Reiterate	Buy -> Buy
2025-10-31	BTIG	Initiate	Buy
2025-08-13	HC Wainwright & Co.	Reiterate	Buy -> Buy
2025-04-01	HC Wainwright & Co.	Reiterate	Buy -> Buy
2025-03-31	HC Wainwright & Co.	Reiterate	Buy -> Buy
2024-09-06	HC Wainwright & Co.	Reiterate	Buy -> Buy
2024-06-13	HC Wainwright & Co.	Reiterate	Buy -> Buy
2024-04-17	HC Wainwright & Co.	Maintains	Buy -> Buy
2024-03-04	HC Wainwright & Co.	Initiate	Buy
2023-09-13	Cantor Fitzgerald	Reiterate	Overweight -> Overweight
2023-02-08	SVB Leerink	Maintains	Outperform
2022-06-02	Cantor Fitzgerald	Initiate	Overweight
2022-05-05	Piper Sandler	Downgrade	Overweight -> Neutral
2022-05-04	SVB Leerink	Maintains	Outperform
2022-01-06	SVB Leerink	Maintains	Outperform
2021-07-02	CICC	Initiate	Outperform
2021-04-13	SVB Leerink	Initiate	Outperform
2021-04-13	Jefferies	Initiate	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: N/A
Period: Q4 / 2025
EPS Estimate: -$1.44
Revenue Estimate: 3.825K
Revenue Q2Q: -99.99%
EPS Q2Q: N/A
Number of Analysts: 7

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

1.67%

EPS (3 Months)

1.67%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth			26.033M	305.531K -98.83%	54.405M 17,706.72%	104.69M 92.43%	23.766M -77.30%	64.427M 171.09%	86.357M 34.04%	215.7M 149.78%	281.98M 30.73%	352.66M 25.07%
EBITDA YoY % growth	-777.18M -24.54%	-71.202M 90.84%	-19.792M 72.20%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-784.12M -24.83%	-71.931M 90.83%	-20.452M 71.57%	-280.646M -1,272.22%	-280.97M -0.12%	-261.337M 6.99%	-67.304M 74.25%	-47.389M 29.59%	-9.6M 79.74%	34.316M 457.45%	84.973M 147.62%	136.96M 61.18%
Operating Margin	N/A	N/A	-78.56%	-91,855.32%	-516.44%	-249.63%	-283.20%	-73.55%	-11.12%	15.91%	30.13%	38.84%
EPS YoY % growth	N/A 40.75%	N/A 59.72%	N/A 73.94%	-4.92 -212.62%	-3.92 20.35%	-3.50 10.82%	-0.79 77.53%	-0.51 35.06%	-0.40 22.00%	0.29 171.79%	0.71 150.00%	1.15 61.43%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q4 / 25	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26
EPS Q2Q % growth	-1.44	-0.33 -71.79%	-0.34 -46.35%	-0.34 -8.58%	-0.35 75.96%
Revenue Q2Q % growth	3.825K -99.99%	N/A	N/A	N/A	N/A
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-82.21M -301.97%	-14.586M 85.20%	-14.892M -10.94%	-15.198M 14.02%	-15.3M 81.39%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

-30.47%

EPS Next 5 Year

10.88%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

-15.95%

Revenue Next 5 Year

-18.23%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CONNECT BIOPHARMA HOLDINGS L / CNTB Forecast FAQ

What do analysts expect the price target to be for CONNECT BIOPHARMA HOLDINGS L (CNTB)?

11 analysts have analysed CNTB and the average price target is 8.06 USD. This implies a price increase of 133.23% is expected in the next year compared to the current price of 3.455.

What are the consensus estimates for CNTB stock next earnings?

The consensus EPS estimate for the next earnings of CONNECT BIOPHARMA HOLDINGS L (CNTB) is -1.44 USD and the consensus revenue estimate is 3.83K USD.

What is the expected long term growth rate for CONNECT BIOPHARMA HOLDINGS L (CNTB)?

The expected long term growth rate for CONNECT BIOPHARMA HOLDINGS L (CNTB) is -15.95%.

Analyst forecast overview

Forecast Snapshot